PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1403413
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1403413
According to Stratistics MRC, the Global Dermal Fillers Market is accounted for $5.5 billion in 2023 and is expected to reach $10.5 billion by 2030 growing at a CAGR of 9.8% during the forecast period. Dermal fillers are less invasive treatments that employ gel-based materials. These are utilized to enhance the appearance of the facial skin and come in the form of injectables. These treatments contribute to a more youthful appearance by minimizing wrinkles. These procedures are helpful in reducing acne scars and are utilized to improve lips and facial wrinkles.
According to WHO estimates, by 2030, one in every six people in the world will be 60 or older. As per statistics, the geriatric population size will get double from 1 billion in 2020 to 2.1 billion in 2050.
A treatment known as minimally-invasive surgery is one that is carried out with the use of specialized surgical tools and a scope for seeing. It reduces extra fat, volume, and contour while focusing on face abnormalities including fine lines and wrinkles. There is a great demand worldwide for minimally invasive energy-based skin tightening, wrinkle reduction, face sculpting, and skin rejuvenation procedures. Thus, the increasing prevalence of minimally invasive procedures is expected to drive growth in the market.
The ingredients used to make permanent dermal fillers are indigestible to the human body. As a result, the body will probably defend itself, which might result in consequences including infections and the development of biofilms. Furthermore, permanent fillers harm the human body irreversibly and are not removed. A rising number of people's concerns about the negative consequences of using dermal fillers may limit the market's evolution to some extent.
Dermal fillers are compounds that resemble gel and are injected beneath the skin to smooth lines, soften wrinkles, and replenish lost volume. Without requiring surgery or downtime, these fillers are a useful therapeutic option for looking younger. This medication is injected beneath the skin to help plump up wrinkles on the face. This medications come in a variety of forms; the most popular ones are hyaluronic acid and calcium hydroxylapatite, among others. Improvements in dermal filler brands will contribute to increased market demand.
Cost is a factor that is taken into account for elective procedures. Dermal filler costs vary based on the kind and quantity utilized in the procedure. The cost of the procedure also depends on the training and experience of the practitioner applying dermal fillers. Dermal filler is a popular cosmetic operation that may restore lost volume and cure various indications of aging. It is a safe outpatient procedure, but the expensive cost of the treatments is anticipated to limit market demand.
The COVID-19 pandemic had a detrimental influence on the cosmetic dermatology and aesthetic medicine industries, which suffered production issues and supply chain interruptions internationally. Lockdown procedures, travel restrictions, and a smaller labor force all contributed to delays in dermal filler manufacture, distribution, and transit, which in turn resulted in shortages and restricted availability in different areas. Furthermore, at the pandemic's height, there were severe restrictions on elective medical procedures, including beauty treatments. This led to the temporary closure of non-essential clinics and a sharp drop in the demand for cosmetic services.
The biodegradable segment is expected to be the largest during the forecast period. They are intended to create a mild, natural-looking augmentation while imitating the facial features. They can be used to improve facial features like the lips and cheeks, fill in wrinkles and fine lines, and add volume to the face. Biodegradable dermal fillers, in contrast to permanent fillers, are intended to progressively degrade and be absorbed by the body over time. This implies that patients can modify their look to suit their changing demands and tastes.
The hyaluronic acid segment is expected to have the highest CAGR during the forecast period. Deep creases, wrinkles, fine lines, and volume loss are just a few of the issues that can be resolved with hyaluronic acid dermal fillers. They may also be used to improve the look of scars and other skin defects, as well as to accentuate the lips and cheekbones. Because they come in various formulations, practitioners may tailor therapies to the specific requirements of each patient.
North America is projected to hold the largest market share during the forecast period. This is due to males are becoming more popular, there is a growing trend of ageless beauty in the area, and there is an increased need for non-surgical cosmetic operations. The region's populace is very conscious of ideals of beauty and physical attractiveness. Because of this, dermal fillers are in high demand as a way to improve face characteristics and lessen aging symptoms.
Asia Pacific is projected to hold the highest CAGR over the forecast period. More people in the area may afford cosmetic operations as disposable income rises. Due to the region's popularity as a medical tourism destination, many individuals come here for cosmetic procedures-the area industry has grown rapidly. In addition, the region's ideals of beauty are evolving, placing an increasing focus on characteristics like big lips and high cheekbones.
Some of the key players in Dermal Fillers market include Allergan , Anika Therapeutics, Inc., BIOXIS Pharmaceuticals, Elan aesthetics Inc, FillMed Laboratories, Galderma Laboratories, L.P., Merz Pharma, Prollenium Medical Technologies, Teoxane Laboratories, Revance Therapeutics, Inc., Sinclair Pharma, Suneva Medical, Vital Esthetique Laboratories, Contura International ltd., Zimmer Aesthetic and BioPlus Co., Ltd.
In April 2023, Sinclair Pharma announced that it has received European CE mark for Perfectha Lidocaine, a hyaluronic acid dermal filler pre-mixed with lidocaine. This will make the filler more comfortable for patients to receive.
In March 2023, Revance Therapeutics announced that it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for TAO, a hyaluronic acid dermal filler for the correction of moderate to severe facial wrinkles and folds.
In February 2023, Galderma received FDA approval for Restylane Defyne, a hyaluronic acid dermal filler for chin augmentation. This is the first FDA-approved dermal filler specifically for chin augmentation.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.